Pompe Disease Market in the US 2015-2019

アメリカのポンペ病治療薬市場2015-2019

◆タイトル:Pompe Disease Market in the US 2015-2019
◆商品コード:IRTNTR7744
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年11月11日
◆ページ数:56
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:米国
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、アメリカのポンペ病治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、アメリカのポンペ病治療薬市場規模及び予測、市場シェア、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About pompe disease
Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action of GAA, an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen in the lysosomes of the cells. The buildup of glycogen in certain organs and tissues, especially in the muscles, hinders the normal functions of the organs. Pompe disease can be further classified as infantile-onset and adult-onset Pompe disease. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and can pass one copy of the mutated gene to their offspring. The disease affects both men and women.

Technavio’s analysts forecast the pompe disease market in the US to grow at a CAGR of 10.68 % over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the pompe disease market in US for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of the drugs available in the US market and the drug candidates that are in various phases of development for the treatment of Pompe disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Technavio’s report, Pompe Disease Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It also covers the landscape of the market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key vendors]
• Amicus Therapeutics
• BioMarin Pharmaceutical
• Genzyme

[Other prominent vendors]
• Audentes Therapeutics
• EpiVax
• Oxyrane
• Sangamo BioSciences
• Valerion Therapeutics

[Market driver]
• Special provision for orphan drugs
• For a full, detailed list, view our report

[Market challenge]
• Limited patient population
• For a full, detailed list, view our report

[Market trend]
• Growing public awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Disease overview
Understanding the disease
Types of Pompe disease
Symptoms
Diagnosis
Etiology and pathogenesis
Epidemiology
Management
Economic burden

PART 07: Orphan drug in the US
Development and regulatory challenges
Orphan drug policies in US

PART 08: Pipeline analysis
Key information on pipeline candidates

PART 09: Market drivers

PART 10: Impact of drivers

PART 11: Market challenges

PART 12: Impact of drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape
Competitive scenario
Market share analysis
Other and future prominent vendors

PART 15: Key vendor analysis
Amicus Therapeutics
BioMarin Pharmaceutical
Genzyme

PART 16: Appendix
List of abbreviation

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Pompe disease market in US 2014-2019 ($ millions)
Exhibit 03: Drivers and challenges for Pompe disease market in US
Exhibit 04: Five forces analysis
Exhibit 05: Snapshot of Pompe disease
Exhibit 06: Classification of Pompe disease
Exhibit 07: Signs and symptoms of Pompe disease
Exhibit 08: Differential diagnosis for Pompe disease in infants
Exhibit 09: Differential diagnosis for Pompe disease in children and adults
Exhibit 10: Biochemical pathway of Pompe disease
Exhibit 11: Approaches to treat Pompe disease
Exhibit 12: Economic burden: Pompe disease
Exhibit 13: Orphan drug development and regulatory challenges
Exhibit 14: Pipeline portfolio of Pompe disease market in US
Exhibit 15: Impact of drivers
Exhibit 16: Impact of drivers and challenges
Exhibit 17: Region wise sales of Myozyme/Lumizyme 2011-2014 ($ millions)
Exhibit 18: Key takeaways: Genzyme
Exhibit 19: Amicus Therapeutics: Ongoing clinical studies
Exhibit 20: BioMarin: Product segmentation by net revenue 2014
Exhibit 21: BioMarin: Segmentation by revenue 2014
Exhibit 22: BioMarin: Segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 23: BioMarin: Geographical segmentation by net revenue 2014
Exhibit 24: Genzyme: Business segmentation by revenue 2014
Exhibit 25: Genzyme: Business segmentation by revenue 2013 and 2014 ($ billions)



【掲載企業】

Amicus Therapeutics, BioMarin Pharmaceutical, Genzyme, Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, Valerion Therapeutics.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[アメリカのポンペ病治療薬市場2015-2019] (Pompe Disease Market in the US 2015-2019 / IRTNTR7744)販売に関する免責事項
[アメリカのポンペ病治療薬市場2015-2019] (Pompe Disease Market in the US 2015-2019 / IRTNTR7744)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆